pastoris(pp), and VEGF165b produced in mammalian cells (hs) were added to HUVECs only or in combination. VEGF121b or VEGF165b (or transporting the PCDNA3.1 empty vector, as control) and xenotransplanted into nude mice showed increased tumor volume and angiogenesis compared to controls. To assess whether the VEGFxxxb isoforms are differentially indicated in tumors compared to healthy cells, immunohistochemical analysis was conducted on a breast cancer cells microarray. A significant increase (p < 0.05) in both VEGFxxxb and total VEGF-A protein expression in infiltrating ductal carcinomas compared to normal breasts was observed. A positive significant correlation (r = 0.404, p = 0.033) between VEGFxxxb and total VEGF-A was found. == Conclusions == Our results demonstrate that VEGF121/165b are not anti-angiogenic, but weakly angiogenic isoforms of VEGF-A. In addition, VEGFxxxb isoforms are up-regulated in breast cancer in comparison with non malignant breast tissues. These results are to be taken into account when considering a possible use of VEGF121/165b-centered therapies in individuals. == BMP10 Background == Angiogenesis is definitely a process by which new blood vessels are created from pre-existing ones [1]. In physiological conditions, this process is definitely strictly controlled by a set of molecules that can either activate the process (proangiogenic factors) or inhibit it (antiangiogenic factors) [2]. During the last decades, it has been widely founded that 5-TAMRA solid tumors have irregular hyperactivation of angiogenesis [2]. Among the factors that can result in angiogenesis, the lack of oxygen (hypoxia) is definitely of unique importance. Virtually all solid tumors eventually activate angiogenesis in order to overcome lack of oxygen and nutrients after reaching a certain burden [3,4]. Probably one of the most important mediators of hypoxia-activated angiogenesis is the Vascular Endothelial Growth Factor (VEGF-A), produced by tumor cells after sensing low 5-TAMRA oxygen levels [5,6]. VEGF-A manifestation can also be induced by non-hypoxia mediated activation, such as Ras signalling [7]. VEGF-A is definitely a key player in tumor-induced angiogenesis, and its overexpression has been found in most solid tumor types [6]. VEGF-A functions through its cognate receptors VEGFR1 (Flt-1) and VEGFR2 (Flk-1/KDR), in endothelial and bone marrow-derived cells [6,8]. The VEGF pathway has been used as a major target to block tumor angiogenesis. A set of molecules that bind and inhibit different components of the VEGF-A pathway have been developed during the past years. Some of them have already reached the medical practice, such as bevacizumab (Avastin, Genentech), a monoclonal antibody that binds and inactivates VEGF-A, or sunitinib (Sutent, Pfizer), a tyrosine-kinase inhibitor that blocks phosphorylation of several tyrosine-kinase receptors including VEGFR1 and VEGFR2 [9,10]. The VEGF-A gene consists of 8 exons, which can give rise to 5 main on the other hand spliced isoforms (VEGF121, VEGF145, VEGF165, VEGF189and VEGF206) [6]. Alternate translation codons upstream of the canonical ATG codon can be used, so that longer isoforms can also be generated [11]. However, the relative importance of these users is still undetermined. Recently, a novel set of isoforms, the so-called “b-isoforms” or “VEGFxxxb” isoforms, have been explained. These transcripts of the VEGF-A gene code for polypeptides with the same size as the classical ones, because exon 8 (present in all the formerly known isoforms) is definitely substituted by an on the other hand spliced exon of the same size (exon 8b) [12]. These isoforms were consequently named VEGF121b, VEGF165b, VEGF189b etc. In the classically analyzed isoforms, exon 8 is known to be important for receptor activation [13]. Therefore, the “b-isoforms”, where exon 8 is definitely substituted by another peptide sequence, were hypothesized to act as potential antagonists of VEGF-A receptors [14]. Several reports possess indeed demonstrated that VEGF165b may have anti-angiogenic properties [14,15], while others cast some doubts about such activities, suggesting that it may act as a VEGF-A receptor agonist [16,17]. Another interesting issue is the possible differential manifestation between “angiogenic” vs. “antiangiogenic” isoforms in pathologies where development of aberrant vasculature is definitely 5-TAMRA involved, including malignancy. Previous studies have shown in a limited number of samples, using semiquantitative RT-PCR, that VEGFxxxb isoforms are highly indicated in normal prostate, colon and kidney compared to their malignant counterparts [14,18,19]. It was proposed that formation of.